New Delhi: Drug maker Ranbaxy Laboratories Ltd is withdrawing a single batch of a version of Roche Holding AG’s Accutane acne medicine from the US market for the second time this year.
Gurgaon-based Ranbaxy voluntarily recalled 40 mg capsules of isotretinoin, the chemical ingredient in Accutane, the company said in a statement on Friday. “A single batch was withdrawn from the US market earlier this year,” Atul Sobti, chief executive officer, said in a July investor call.
Roche, based in Basel, Switzerland, said in June that it was pulling Accutane from the US market because of competition from generic versions. The decision came after juries awarded at least $33 million (around Rs155 crore) in damages to users who blamed the drug for causing bowel disease.